Grufity logoGrufity logo
ScreenerStocksFundsSectorsWatchlists
CYTK

Cytokinetics Inc

CYTK

34.10USD-0.76 (-2.18%)Market Closed
Watchlist

Market Summary

USD34.10-0.76
Market Closed
-2.18%

CYTK Alerts

  • 1 major insider sales recently.

CYTK Stock Price

View Fullscreen

CYTK RSI Chart

CYTK Alerts

CYTK Valuation

Market Cap

3.1M

Price/Earnings (Trailing)

-0.01

Price/Sales (Trailing)

0.39

Price/Free Cashflow

-0.01

CYTK Price/Sales (Trailing)

CYTK Profitability

Return on Equity

120.04%

Return on Assets

-71.12%

Free Cashflow Yield

-14.5K%

CYTK Fundamentals

CYTK Revenue

Revenue (TTM)

7.8M

Revenue Y/Y

-84.97%

Revenue Q/Q

-56.4%

CYTK Earnings

Earnings (TTM)

-526.7M

Earnings Y/Y

9.06%

Earnings Q/Q

-0.61%

Price Action

Last 7 days

1.6%

Last 30 days

-1.9%

Last 90 days

-5.4%

Trailing 12 Months

-5.3%

How does CYTK drawdown profile look like?

CYTK Financial Health

Current Ratio

7.22

CYTK Investor Care

Diluted EPS (TTM)

-5.58

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202398.1M10.0M7.8M0
202276.5M82.5M88.5M94.6M
202158.6M57.8M21.6M70.4M
202022.2M18.7M54.3M55.8M
201934.7M35.6M31.0M26.9M
201817.9M22.4M27.0M31.5M
2017102.1M99.4M46.5M13.4M
201632.7M31.9M83.0M106.4M
201543.4M42.1M40.7M28.7M
201437.8M44.6M49.5M46.9M
20136.6M5.7M8.5M30.6M
20125.1M5.8M6.1M7.6M
20112.9M3.3M4.3M4.0M
201061.8M42.1M22.3M2.6M
200900081.5M
Get all data in R, Python etc through our Historical Stock Data APIs

Latest Insider Trading transactions for CYTK

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Nov 30, 2023
blum robert i
acquired
83,375
6.67
12,500
president & ceo
Nov 30, 2023
blum robert i
sold
-412,375
32.99
-12,500
president & ceo
Nov 15, 2023
blum robert i
acquired
83,375
6.67
12,500
president & ceo
Nov 15, 2023
blum robert i
sold
-432,125
34.57
-12,500
president & ceo
Nov 09, 2023
malik fady ibraham
sold
-88,500
35.4
-2,500
evp research & development
Oct 30, 2023
blum robert i
acquired
83,375
6.67
12,500
president & ceo
Oct 30, 2023
blum robert i
sold
-402,125
32.17
-12,500
president & ceo
Oct 16, 2023
blum robert i
sold
-421,250
33.7
-12,500
president & ceo
Oct 16, 2023
blum robert i
acquired
83,375
6.67
12,500
president & ceo
Oct 12, 2023
malik fady ibraham
sold
-89,725
35.89
-2,500
evp research & development

1–10 of 50

Which funds bought or sold CYTK recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Dec 07, 2023
Hudson Bay Capital Management LP
added
700
4,061,200
4,713,600
 0.02%
Dec 06, 2023
CITIGROUP INC
reduced
-18.68
-1,520,550
4,204,350
 -%
Nov 30, 2023
Neo Ivy Capital Management
new
-
470,000
470,000
 0.21%
Nov 24, 2023
DEUTSCHE BANK AG\
added
2.81
-468,819
6,091,360
 -%
Nov 22, 2023
KBC Group NV
unchanged
-
-
242,000
 -%
Nov 22, 2023
Polar Capital Holdings Plc
unchanged
-
-8,388,050
78,200,000
 0.58%
Nov 22, 2023
Public Sector Pension Investment Board
reduced
-30.11
-2,042,210
3,495,490
 0.03%
Nov 21, 2023
COMERICA BANK
new
-
1,322,720
1,322,720
 0.01%
Nov 16, 2023
IRONWOOD INVESTMENT MANAGEMENT LLC
reduced
-2.3
-243,835
1,829,520
 1.12%
Nov 15, 2023
JANE STREET GROUP, LLC
new
-
9,834,660
9,834,660
 -%

1–10 of 30

Latest Funds Activity

Are funds buying CYTK calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own CYTK
No. of Funds

Schedule 13G FIlings of Cytokinetics Inc

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 10, 2023
blackrock inc.
16.7%
15,767,874
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 09, 2023
vanguard group inc
10.64%
10,073,094
SC 13G/A
Feb 06, 2023
wellington management group llp
6.91%
6,542,724
SC 13G
Feb 03, 2023
state street corp
5.33%
5,044,914
SC 13G/A
Jan 26, 2023
blackrock inc.
16.0%
14,967,317
SC 13G/A
Jan 20, 2023
blackrock inc.
16.0%
14,967,317
SC 13G/A
Apr 08, 2022
vanguard group inc
10.30%
8,741,124
SC 13G/A
Feb 14, 2022
driehaus capital management llc
2.77%
2,327,112
SC 13G/A
Feb 09, 2022
vanguard group inc
8.33%
6,989,719
SC 13G/A

Recent SEC filings of Cytokinetics Inc

View All Filings
Date Filed Form Type Document
Dec 01, 2023
4
Insider Trading
Nov 30, 2023
144
Notice of Insider Sale Intent
Nov 17, 2023
8-K
Current Report
Nov 15, 2023
144
Notice of Insider Sale Intent
Nov 15, 2023
4
Insider Trading
Nov 09, 2023
144
Notice of Insider Sale Intent
Nov 09, 2023
4
Insider Trading
Nov 03, 2023
10-Q
Quarterly Report
Nov 02, 2023
8-K
Current Report
Oct 30, 2023
144
Notice of Insider Sale Intent

Peers (Alternatives to Cytokinetics Inc)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
HILS
31.5B
-
 6.13% 411799.31%
-3.7K
218.4K
 - -102.45%
MRNA
30.6B
10.7B
 12.59% -56.51%
-8.83
2.87
 -53.67% -129.46%
ALNY
21.3B
1.7B
 0.38% -28.56%
-41.84
12.38
 79.37% 56.87%
BMRN
17.5B
2.3B
 8.71% -10.95%
119.09
7.58
 15.05% 75.21%
INCY
12.3B
3.6B
 1.18% -34.97%
28.84
3.4
 8.35% -51.49%
MID-CAP
APLS
7.4B
272.9M
 33.62% 24.68%
-12.26
27.23
 141.38% 4.43%
BBIO
5.7B
-
 10.65% 240.88%
-9.69
48.33
 54.84% -12.96%
ACAD
3.4B
631.9M
 -9.53% 43.40%
-23.12
5.44
 23.54% 31.53%
AXSM
3.3B
223.4M
 14.00% -9.85%
-16.45
14.86
 - -26.24%
ARWR
2.6B
240.7M
 -11.63% -24.14%
-12.52
10.67
 -1.03% -16.59%
SMALL-CAP
CPRX
1.5B
348.4M
 12.92% -15.71%
24.33
4.33
 81.69% -7.29%
NVAX
661.3M
1.0B
 -18.09% -67.84%
-1.2
0.63
 -43.15% 58.48%
INO
100.5M
6.4M
 - -79.35%
-0.61
15.6
 -44.11% 50.48%
IBIO
37.6M
-
 385.71% 119.35%
-0.58
-
 - -29.23%
CRBP
23.7M
-
 40.31% 4064.72%
-0.5
-
 - -13.74%

Cytokinetics Inc News

Latest updates
InvestorsObserver • 07 Dec 2023 • 06:33 pm • 2 days ago
Cytokinetics, Inc. (CYTK) is higher by 4.33% in a Week, Should You Buy?
The Pioneer • 02 Nov 2023 • 08:35 pm • 37 days ago
Cytokinetics: Q3 Earnings Snapshot
Barchart • 02 Nov 2023 • 02:30 pm • 37 days ago
The White House Has Proposed Cracking Down On Junk Fees ...
Nasdaq • 02 Nov 2023 • 07:00 am • 37 days ago
Stock Index Futures Climb on Hopes of End to Fed Rate Hikes ...
Nasdaq • 06 Oct 2023 • 07:00 am • 2 months ago
Noteworthy Friday Option Activity: CYTK, FSLR, TTD
The Business Journals • 04 Oct 2023 • 07:00 am • 2 months ago
Tenaya Therapeutics' heart disease treatments climb toward fresh ...
Business Insider • 16 Jun 2023 • 07:00 am • 5 months ago
21 Growth Stocks Most Held by Small-Cap Funds: Fintel
Reuters • 31 Mar 2023 • 07:00 am • 8 months ago
Cytokinetics to focus on heart disease drug after ALS trial failure
Nasdaq • 22 Mar 2023 • 07:00 am • 8 months ago
Want Diversified Upside in Biotechnology? Check out LABU
IG UAE (English) • 08 Jun 2022 • 04:20 pm • 18 months ago
Most Traded Shares in the UAE | What are the Top Stocks
Investor's Business Daily • 31 Dec 2021 • 08:00 am • 23 months ago
100 Best Stocks Of 2021: See Who Joins Moderna And BioNTech
Investing.com • 07 Oct 2021 • 07:00 am • 2 years ago
Mizuho Securities Stick to Their Buy Rating for Cytokinetics By ...
Nasdaq • 08 Oct 2020 • 07:00 am • 3 years ago
BUZZ-U.S. STOCKS ON THE MOVE-Eaton Vance, IBM, Domino's ...
BioWorld Online • 05 Oct 2020 • 07:00 am • 3 years ago
Myosins for givin': $13.1B takeover by BMS blesses Myokardia ...
InvestorIdeas.com • 30 Aug 2018 • 06:22 pm • 5 years ago
Free biotech stocks directory, pharma stocks, telemedicine stocks ...

Financials for Cytokinetics Inc

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue-56.4%0.001.005.002.003.0089.0072.0056.005.003.007.007.0042.004.004.005.006.007.008.009.0011.00
Operating Expenses-0.2%12312312912911110079.0077.0075.0058.0047.0043.0037.0036.0034.0029.0030.0034.0033.0031.0029.00
  S&GA Expenses1.0%40.0040.0050.0054.0048.0043.0033.0034.0026.0021.0016.0014.0012.0014.0012.0011.0010.0010.009.007.007.00
  R&D Expenses-0.8%83.0083.0079.0075.0063.0057.0046.0043.0048.0036.0032.0029.0024.0022.0022.0018.0020.0024.0024.0024.0021.00
EBITDA Margin---------1.24*-4.09*-1.53*-1.51*-1.59*-1.65*-4.96*-4.29*-3.66*-3.24*-2.84*-2.92*--
Interest Expenses1.3%7.007.007.007.007.003.003.004.004.004.004.004.004.004.004.003.001.001.001.001.001.00
EBT Margin---------1.51*-4.93*-1.84*-1.82*-1.90*-1.96*-5.69*-4.78*-3.96*-3.43*-2.98*-3.06*--
Net Income-0.6%-129-128-131-137-142-19.82-89.44-30.57-76.09-61.55-47.10-43.93-3.17-40.78-39.40-30.64-29.57-32.11-29.37-26.47-22.02
Net Income Margin-24.3%-67.40*-54.22*-4.55*-4.11*-3.19*-3.07*-3.66*-3.06*-10.61*-2.69*-2.31*-2.28*-2.10*-7.51*-------
Free Cashflow21.3%-96.43-122-122-101-90.37-91.33-27.75-62.47-54.47-38.29-36.1546.0012.00-28.30-31.18------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets-5.0%7417808901,0151,076772856841828564577534474232257290187198199211230
  Current Assets-4.3%561587681795884602624536495364433474418219226234177185186208227
    Cash Equivalents45.2%10069.0010266.0010694.0011511391.0037.0045.0083.0020161.0050.0036.0040.0034.0039.0042.0028.00
  Net PPE-2.1%76.0077.0079.0080.0080.0079.0076.0073.0054.0037.0023.0013.008.006.005.005.004.003.003.003.003.00
Liabilities6.0%1,1791,1131,1191,1231,092660740597579548509420325311302301207203195185178
  Current Liabilities18.4%78.0066.0075.0085.0076.0067.0067.0072.0081.0062.0036.0031.0028.0023.0021.0026.0022.0022.0026.0022.0021.00
    LT Debt, Current---------17.0011.006.00-------6.003.004.00
    LT Debt, Non Current-2.6%61.0062.0064.0064.0064.0062.0061.0047.0030.0036.0041.0046.0046.0046.0045.0045.0045.0044.0036.0040.0038.00
Shareholder's Equity-31.7%-438-333-229-107-15.9811111624424916.0068.00113150-----3.0026.0052.00
  Retained Earnings-9.7%-1,975-1,800-1,717-1,585-1,448-1,306-1,286-1,207-1,177-1,100-1,039-992-948-945-904-865-834-804-772-743-714
  Additional Paid-In Capital1.5%1,5371,5141,4901,4821,4381,4221,4061,4521,4261,1171,1071,1051,097866857853814799775769766
Shares Outstanding----95.00---85.00---71.00---59.00---55.0054.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations21.0%-96.21-121-122-98.19-84.04-90.47-26.81-44.74-38.77-29.50-29.5252.0014.00-27.44-30.13-19.05-20.27-24.68-26.91-12.33-32.23
  Share Based Compensation0.3%19.0019.0015.0013.0013.0012.009.007.008.007.005.005.005.005.004.003.003.003.002.00--
Cashflow From Investing-11.1%73.0082.0016529.00-29265.00-64.2847.00-20819.00-5.28-173-10135.0043.00-10514.00-2.7720.0027.003.00
Cashflow From Financing890.3%54.005.00-7.1830.003893.0094.0020.003013.00-3.604.002264.00-0.0112112.0022.004.000.0010.00

CYTK Income Statement

2023-09-30
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenues:    
Total revenues$ 378$ 2,515$ 5,858$ 92,631
Operating expenses:    
Research and development82,53262,734245,147165,795
General and administrative40,11148,222129,498124,008
Total operating expenses122,643110,956374,645289,803
Operating loss(122,265)(108,441)(368,787)(197,172)
Interest expense(7,136)(6,804)(21,142)(12,357)
Loss on extinguishment of debt0(22,246)0(24,939)
Non-cash interest expense on liabilities related to revenue participation right purchase agreements(6,860)(8,963)(19,462)(22,530)
Interest and other income, net6,8394,14420,0435,423
Net loss$ (129,422)$ (142,310)$ (389,348)$ (251,575)
Net loss per share - basic$ (1.35)$ (1.52)$ (4.07)$ (2.85)
Net loss per share - diluted$ (1.35)$ (1.52)$ (4.07)$ (2.85)
Weighted-average number of shares used in computing net loss per share - basic96,07193,75895,66688,195
Weighted-average number of shares used in computing net loss per share - diluted96,07193,75895,66688,195
Other comprehensive income (loss):    
Unrealized gain (loss) on available-for-sale securities, net$ 584$ (1,065)$ 2,716$ (4,690)
Comprehensive loss(128,838)(143,375)(386,632)(256,265)
Research and Development Revenues [Member]    
Revenues:    
Total revenues3782,5153,3584,631
Milestone Revenues [Member]    
Revenues:    
Total revenues002,5001,000
Realization of Revenue Participation Right Purchase Agreement [Member]    
Revenues:    
Total revenues$ 0$ 0$ 0$ 87,000

CYTK Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 99,692$ 65,582
Short-term investments439,547716,995
Accounts receivable2,499147
Prepaid expenses and other current assets19,67812,462
Total current assets561,416795,186
Long-term investments15,46846,708
Property and equipment, net75,61480,453
Operating lease right-of-use assets79,92982,737
Other assets8,1879,691
Total assets740,6141,014,775
Current liabilities:  
Accounts payable13,79625,611
Accrued liabilities32,95444,096
Short-term operating lease liabilities17,23612,829
Other current liabilities13,7372,081
Total current liabilities77,72384,617
Term loan, net60,88563,810
Convertible notes, net548,134545,808
Liabilities related to revenue participation right purchase agreement, net370,049300,501
Long-term operating lease liabilities122,216126,895
Other non-current liabilities4081,044
Total liabilities1,179,4151,122,675
Commitments and contingencies
Stockholders' deficit:  
Preferred stock, $0.001 par value00
Common stock, $0.001 par value9494
Additional paid-in capital1,537,3211,481,590
Accumulated other comprehensive loss(874)(3,590)
Accumulated deficit(1,975,342)(1,585,994)
Total stockholders' deficit(438,801)(107,900)
Total liabilities and stockholders' deficit$ 740,614$ 1,014,775

About Cytokinetics Inc

CYTK
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.
 CEO
 WEBSITEwww.cytokinetics.com
 EMPLOYEES409

Cytokinetics Inc Frequently Asked Questions

What is the ticker symbol for Cytokinetics Inc? What does CYTK stand for in stocks?

CYTK is the stock ticker symbol of Cytokinetics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Cytokinetics Inc (CYTK)?

As of Fri Dec 08 2023, market cap of Cytokinetics Inc is 3.07 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CYTK stock?

You can check CYTK's fair value in chart. The fair value of Cytokinetics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Cytokinetics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CYTK so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Cytokinetics Inc a good stock to buy?

The fair value guage provides a quick view whether CYTK is over valued or under valued. Whether Cytokinetics Inc is cheap or expensive depends on the assumptions which impact Cytokinetics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CYTK.

What is Cytokinetics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 08 2023, CYTK's PE ratio (Price to Earnings) is -0.01 and Price to Sales (PS) ratio is 0.39. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CYTK PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Cytokinetics Inc's stock?

In the past 10 years, Cytokinetics Inc has provided 0.186 (multiply by 100 for percentage) rate of return.